ALS Drug, Riluzole, Being Tested in Alzheimer’s Patients May Work by Protecting Neurons

ALS Drug, Riluzole, Being Tested in Alzheimer’s Patients May Work by Protecting Neurons
Riluzole, a drug approved for the treatment of amyotrophic lateral sclerosis (ALS), might reverse genetic changes often observed in patients with Alzheimer’s disease and age-related cognitive decline. The findings support a clinical trial now exploring if riluzole is beneficial for Alzheimer’s patients. Researchers at Rockefeller University have previously shown that riluzole can prevent memory loss in aging rats by inducing structural brain changes. Now, the team led by Ana Pereira, an instructor in clinical medicine in Bruce McEwen's laboratory at Rockefeller, further explored how the drug might affect the neurotransmitter glutamate in the hippocampus, a brain region crucial for memory processing. "In aging and Alzheimer's, the chemica
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *